When GE Healthcare's Shanghai facility closed in 2022, the iodinated contrast media supply was disrupted. However, a new study found that new technological advances have addressed limitations in the use of pulmonary MR angiography (MRA) for pulmonary embolus (PE) diagnosis.
According to an accepted manuscript published in the American Journal of Roentgenology (AJR), the preferential use of MRA for diagnosing PE in the general population helped conserve iodinated contrast media during last year's shortage.
"This single-center experience demonstrates use of pulmonary MRA as a practical substitute for pulmonary CTA in emergency settings," concluded lead investigator Jitka Starekova, MD, from the radiology department of the University of Wisconsin in Madison.
Starekova et al.’s study included all CTA and MRA examinations performed to exclude PE at their large academic medical center (University of Wisconsin-Madison Hospital and Clinics) from April 1 through July 31 (18 weekly periods) in:
- 2019 (before the COVID-19 pandemic and contrast media shortage),
- 2021 (during the pandemic, though before the shortage),
- 2022 (during both the pandemic, as well as the shortage).
To help preserve iodinated contrast media, from early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis. Upon reviewing CTA and MRA reports, Starekova and her AJR colleagues estimated iodinated contrast media savings via preferential MRA usage.
Ultimately, preferred use of pulmonary MRA to diagnosis PE among the general population conserved (from April 1 to July 31, 2022) an estimated 27 liters of iohexol (Omnipaque) 350mg/ml. During weeks 8-11, more MRA examinations (range, 45-63) than CTA examinations (range, 27-46) were performed.
Noting their AJR accepted manuscript evaluated MRA for PE diagnosis in “an all-comer real-world setting,” the present study also includes a larger sample size in comparison to previous research.
